Inhalation atomizer comprising a blocking function and a counter

1. An inhalation atomizer comprising:

(a) a counter comprising a worm, a counter ring, and an upper shell, wherein the counter ring is circular with a bottom having an indentation, the worm has an upper end gear and a lower end gear, which contact the upper shell, and the upper shell comprises an inside bulge, and when the bulge passes through the upper end gear of the worm, the worm is driven to rotate, which drives rotation of the counter ring through the lower end gear, resulting in a counting effect;

(b) a blocking function comprising a locking mechanism which comprises a lower unit, wherein a lower unit comprises (i) a first protrusion which is nested in the indentation of the counter ring and (ii) a second protrusion, wherein the first protrusion and second protrusion are on the same horizontal level and able to move and rotate in the indentation, such that when the inhalation atomizer is actuated, the counter ring rotates around the lower unit with a constant angle, and when the first and second protrusions encounter each other, the counter is prevented from further rotation, locking the atomizer and stopping it from further use;

(c) a fluid in a vessel;

(d) a nozzle for the delivery and atomization of the fluid, wherein the fluid is delivered in metered individual full-doses; and

(e) a delivering element in the form of a delivering tube, which is movable for delivering and atomizing the fluid.

2. The inhalation atomizer according to claim 1 , wherein the fluid contains a solvent.

3. The atomizer according to claim 1 , wherein the fluid comprises a pharmaceutical active ingredient selected from the group consisting of anticholinergics, betamimetics, steroids, phosphodiesterase IV-inhibitors, LTD4-antagonists and EGFR-kinase-inhibitors, antiallergics, ergot alkaloid derivatives, triptans, CGRP-antagonists, phosphodiesterase-V-inhibitors, and any combination of the foregoing.

4. The inhalation atomizer according to claim 1 , wherein the fluid comprises a pharmaceutical active ingredient selected from the group consisting of aclidinium bromide, formoterol fumarate, indacaterol maleate, glycopyrrolate bromide, fluticasone furoate, vilanterol trifenatate, umeclidinium bromide, tiotropium bromide, olodaterol hydrochloride, ipratropium bromide, albuterol sulfate, any pharmaceutically acceptable salts thereof, and any combination thereof.

5. The inhalation atomizer according to claim 1 , wherein the fluid comprises a pharmaceutical active ingredient selected from the group consisting of a combination of aclidinium bromide and formoterol fumarate.

6. The inhalation atomizer according to claim 1 , wherein the fluid comprises a pharmaceutical active ingredient selected from the group consisting of a combination of indacaterol maleate and glycopyrrolate bromide, and any pharmaceutically acceptable salts thereof.

7. The inhalation atomizer according to claim 1 , wherein the fluid comprises a pharmaceutical active ingredient selected from the group consisting of a combination of fluticasone furoate and vilanterol trifenatate.

8. The inhalation atomizer according to claim 1 , wherein the fluid comprises a pharmaceutical active ingredient selected from the group consisting of a combination of fluticasone furoate, vilanterol trifenatate and umeclidinium bromide, and any pharmaceutically acceptable salts thereof.

9. The inhalation atomizer according to claim 1 , wherein the fluid comprises a pharmaceutical active ingredient selected from the group consisting of tiotropium bromide and any pharmaceutically acceptable salts thereof.

10. The inhalation atomizer according to claim 1 , wherein the fluid comprises a pharmaceutical active ingredient selected from the group consisting of a combination of tiotropium bromide and olodaterol hydrochloride, and any pharmaceutically acceptable salts thereof.

11. The inhalation atomizer according to claim 1 , wherein the fluid comprises a pharmaceutical active ingredient selected from the group consisting of olodaterol hydrochloride and any pharmaceutically acceptable salts thereof.

12. The inhalation atomizer according to claim 1 , wherein the fluid comprises a pharmaceutical active ingredient selected from the group consisting of a combination of ipratropium bromide and albuterol sulfate, and any pharmaceutically acceptable salts thereof.

13. A method for inhalation delivery of an atomized fluid in individual, metered full-doses through a nozzle, comprising atomizing a fluid with the inhalation atomizer of claim 1 .

14. A blocking function comprising a locking mechanism and a counter, wherein:

(a) the counter comprises a worm and a counter ring, wherein the counter ring is circular having a bottom with a continuous indentation, the worm has an upper end gear and a lower end gear that contact an upper shell, and the upper shell comprises an inside bulge, such that when the bulge passes through the upper end gear of the worm, the worm is driven to rotate, which drives rotation of the counter ring through the lower end gear, resulting in a counting effect; and

(b) the blocking function comprises a lower unit, which comprises (i) a first protrusion which is nested in the continuous indentation of the counter ring and (ii) a second protrusion, wherein the first protrusion and second protrusion are on the same horizontal level and able to move and rotate in the continuous indentation, such that when the inhalation atomizer is actuated, the counter ring rotates around the lower unit with a constant angle, and when the first and second protrusions encounter each other, the counter is prevented from further rotation, locking the atomizer and stopping it from further use.